Stifel analyst Eric Le Berrigaud upgraded Novartis to Buy from Hold with a price target of CHF 97, up from CHF 89. The analyst says his "icrementally positive stance" on Pluvicto for advanced prostate cancer and Kisqali for breast cancer more than offsets his more conservative view towards cholesterol drug Leqvio. Le Berrigaud expects a "reversal of investor sentiment towards Novartis."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVS:
